Features
Automated LVEF calculation from standard DICOM echo studies
AI detection of cardiac amyloidosis from A4C and PLAX views
FDA 510(k) clearance for Precision LVEF and Precision Cardiac Amyloid
Prospective randomized controlled trial published in Nature
DICOM-native post-processing (no new hardware or scanners)
PACS and Epic EHR integration
CPT Category III code 0932T for reimbursement (effective Jan 1, 2025)
Breakthrough Device designation and FDA TAP enrollment for cardiac amyloid
Zero marginal clinician burden per study
Multi-indication pipeline (LVEF, amyloid, cirrhosis, reporting, valve disease)
Developed in collaboration with Alexion (AstraZeneca Rare Disease)
Clinically validated in peer-reviewed journals
Precision Cirrhosis for opportunistic liver disease detection
Precision Reporting with EchoPrime foundation model
Multi-valve algorithms (mitral, tricuspid, aortic in development)
Foundation model vBx-1.0 for precision neurology
Multimodal patient brain dataset: 12,000+ brains, 6,000 patients
Paired proteomic, genomic, and clinical data per patient
Physical inventory of 900+ frozen brain tissue samples
Virtual biopsy model predicts brain activity from blood draw
Target discovery from proprietary human data
Target characterization with 83% preclinical validation rate
Biomarker identification for clinical trials
Patient stratification for trial enrichment
Lifts responder fraction from 52% to 69% (vBx-1.0)
Reduces trial enrollment by 43% in Parkinson's (L-DOPA responders)
Platform for target discovery, characterization, biomarkers, and stratification
Supports Parkinson's, Alzheimer's, and other neurodegenerative diseases
Partnership model with top-20 pharma collaborations
